Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Hoog

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Investigation|March 27, 2012
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsCynthia X Ma, Shirong Cai, Shunqiang Li, et al.
Cell Reports|February 17, 2021
Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1Cuige Zhu, Sun-Joong Kim, Arshag Mooradian, et al.
Cancers|December 29, 2020
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft ModelsZhanfang Guo, Tina Primeau, Jingqin Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal womenAnita K Dunbier, Helen Anderson, Zara Ghazoui, et al.
The Journal of Molecular Diagnostics : JMD|December 21, 2016
An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast TumorsJingqin Luo, Shuzhen Liu, Samuel Leung, et al.
Breast Cancer Research and Treatment|October 22, 2009
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis, Li Lin, Robert Crowder, et al.
Breast Cancer Research : BCR|November 23, 2017
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba Bagegni, Shana Thomas, Ning Liu, et al.
Cancer Research Communications|May 8, 2024
Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft ModelsZhanfang Guo, Jingqin Luo, R Jay Mashl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2015
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Michael Naughton, et al.
Cancer Research|April 16, 2009
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancerRobert J Crowder, Chanpheng Phommaly, Yu Tao, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Investigation|March 27, 2012
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsCynthia X Ma, Shirong Cai, Shunqiang Li, et al.
Cell Reports|February 17, 2021
Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1Cuige Zhu, Sun-Joong Kim, Arshag Mooradian, et al.
Cancers|December 29, 2020
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft ModelsZhanfang Guo, Tina Primeau, Jingqin Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal womenAnita K Dunbier, Helen Anderson, Zara Ghazoui, et al.
The Journal of Molecular Diagnostics : JMD|December 21, 2016
An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast TumorsJingqin Luo, Shuzhen Liu, Samuel Leung, et al.
Breast Cancer Research and Treatment|October 22, 2009
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis, Li Lin, Robert Crowder, et al.
Breast Cancer Research : BCR|November 23, 2017
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba Bagegni, Shana Thomas, Ning Liu, et al.
Cancer Research Communications|May 8, 2024
Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft ModelsZhanfang Guo, Jingqin Luo, R Jay Mashl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2015
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Michael Naughton, et al.
Cancer Research|April 16, 2009
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancerRobert J Crowder, Chanpheng Phommaly, Yu Tao, et al.
Pageof 5